Glaukos Corporation Announces Pricing of Its Initial Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $18.00 per share. The offering is scheduled to close on June 30, 2015, subject to customary closing conditions. The underwriters for the offering will also have a 30-day option to purchase up to an additional 900,000 shares of Glaukos common stock at the price to the public, less the underwriting discounts and commissions.

Glaukos’s common stock is expected to begin trading on the New York Stock Exchange on June 25, 2015, under the symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. William Blair and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on June 24, 2015. The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Phone: (866) 803-9204; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com; or Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526 or e-mail at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Glaukos
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos launched iStent Trabecular Micro-Bypass Stent, the industry's first Micro-Invasive Glaucoma Surgery (MIGS) device, in the United States in 2012. The company is based in Laguna Hills, CA.